康莱特注射液在晚期非小细胞肺癌患者中的疗效观察及对T淋巴细胞水平的影响研究
|
摘要
目的:探讨康莱特注射液在晚期非小细胞肺癌患者中的疗效观察及对T淋巴细胞水平的影响。方法:选择2011年7月～2015年3月以晚期非小细胞肺癌收治的患者120例作为研究对象,根据治疗方案分为对照组(n=60)和观察组(n=60)。对照组采用单纯化疗治疗,观察组在对照组基础上联合康莱特注射液治疗,两组均治疗4个疗程,治疗完毕后对患者效果进行评估。根据世界卫生组织(WHO)疗效评定标准从完全缓解(CR)、部分缓解(PR)、稳定(SD)及进展(PD)对患者疗效率进行评估;采用流式细胞仪测定两组治疗前、治疗4疗程后CD3~+、CD4~+、CD8~+及CD4~+/CD8~+水平;记录并统计两组治疗后气促乏力、胸痛、咳嗽、发热、咯血及吞咽困难发生率;两组治疗后均进行3年随访,记录并统计患者治疗后生存期,比较两组治疗效果及对T淋巴细胞水平的影响。结果:观察组采用康莱特注射液4个疗程的近期疗效率为53. 33%,高于对照组38. 33%(P<0. 05);观察组治疗4个疗程后CD3~+、CD4~+、CD8~+及CD4~+/CD8~+水平均高于对照组(P<0. 05)。观察组与对照组治疗后气促乏力、胸痛、咳嗽、发热、咯血及吞咽困难发生率差异无统计学意义(P>0. 05)。治疗后对患者进行3年随访,观察组中位生存期为(18. 35±3. 21)个月长于对照组(13. 29±2. 95)个月(P<0. 05);观察组3年生存率为41. 67%(25/60)高于对照组25. 00%(15/60)(P<0. 05)。结论:将康莱特注射液用于晚期非小细胞肺癌患者中能获得较高疗效,能提高机体免疫水平,药物安全性较高,能延长患者生存期,值得推广应用。
Objective: To investigate the effect of Kanglaite injection in patients with advanced non-small cell lung cancer and its effect on the level of T lymphocytes. Methods: A total of 120 patients who were treated with advanced non-small cell lung cancer from July 2011 to March 2015 were selected and divided into a control group( n = 60) and an observation group( n = 60) according to the treatment plan. The control group was treated with chemotherapy alone,and the observation group was treated with Kanglaite injection on the basis of the control group. Both groups were treated for 4 courses and the effect of the treatment was evaluated after the treatment. Evaluate the efficacy rate of patients with complete remission( CR),partial remission( PR),stabilization( SD),and progression( PD) according to the evaluation criteria of WHO( World Health Organization). Flow cytometry was used to measure the two groups before treatment,after treatment,CD3~+,CD4~+,CD8~+and CD4~+/CD8~+levels were recorded for 4 courses; the incidences of dyspepsia,chest pain,cough,fever,hemoptysis and dysphagia after treatment were recorded and calculated. All patients were followed up for 3 years after treatment. The survival period of patients after treatment was counted,and the effect of treatment and the level of T lymphocytes were compared. Results: The short-term efficacy rate of Kanglaite injection in the observation group was 53. 33%,which was higher than that in the control group 38. 33%( P<0. 05). The levels of CD3~+,CD4~+,CD8~+and CD4~+/CD8~+ in the observation group after 4 courses of treatment were both observed higher than the control group( P<0. 05). There was no significant difference in the rates of post-treatment fatigue,chest pain,cough,fever,hemoptysis and dysphagia between the observation group and the control group( P >0. 05). The patients were followed up for 3 years after treatment. The median survival time of the observation group was( 18. 35±3. 21)months longer than that of the control group( 13. 29 ± 2. 95) months( P < 0. 05); the 3-year survival rate of the observation group was41. 67%( 25/60) higher than the control group 25. 00%( 15/60)( P<0. 05). Conclusion: Kanglaite injection used in advanced nonsmall cell lung cancer patients can obtain a higher effect,can improve the body's immune level,drug safety,can prolong the survival of patients,it is worth promoting.
Objective: To investigate the effect of Kanglaite injection in patients with advanced non-small cell lung cancer and its effect on the level of T lymphocytes. Methods: A total of 120 patients who were treated with advanced non-small cell lung cancer from July 2011 to March 2015 were selected and divided into a control group( n = 60) and an observation group( n = 60) according to the treatment plan. The control group was treated with chemotherapy alone,and the observation group was treated with Kanglaite injection on the basis of the control group. Both groups were treated for 4 courses and the effect of the treatment was evaluated after the treatment. Evaluate the efficacy rate of patients with complete remission( CR),partial remission( PR),stabilization( SD),and progression( PD) according to the evaluation criteria of WHO( World Health Organization). Flow cytometry was used to measure the two groups before treatment,after treatment,CD3~+,CD4~+,CD8~+and CD4~+/CD8~+levels were recorded for 4 courses; the incidences of dyspepsia,chest pain,cough,fever,hemoptysis and dysphagia after treatment were recorded and calculated. All patients were followed up for 3 years after treatment. The survival period of patients after treatment was counted,and the effect of treatment and the level of T lymphocytes were compared. Results: The short-term efficacy rate of Kanglaite injection in the observation group was 53. 33%,which was higher than that in the control group 38. 33%( P<0. 05). The levels of CD3~+,CD4~+,CD8~+and CD4~+/CD8~+ in the observation group after 4 courses of treatment were both observed higher than the control group( P<0. 05). There was no significant difference in the rates of post-treatment fatigue,chest pain,cough,fever,hemoptysis and dysphagia between the observation group and the control group( P >0. 05). The patients were followed up for 3 years after treatment. The median survival time of the observation group was( 18. 35±3. 21)months longer than that of the control group( 13. 29 ± 2. 95) months( P < 0. 05); the 3-year survival rate of the observation group was41. 67%( 25/60) higher than the control group 25. 00%( 15/60)( P<0. 05). Conclusion: Kanglaite injection used in advanced nonsmall cell lung cancer patients can obtain a higher effect,can improve the body's immune level,drug safety,can prolong the survival of patients,it is worth promoting.
引文
[1]郭卫东.探析DC-CIK联合化疗治疗晚期非小细胞肺癌的临床效果[J].中华肿瘤防治杂志,2016,23(5):335-336.Guo WD. Discussion on the clinical efficacy of DC-CIK combined with chemotherapy in the treatment of advanced non-small cell lung cancer[J]. Chin J Cancer Prevention Treatment,2016,23(5):335-336.
[2] Küchler A,Buser F,Bley CR,et al. MDM2 immunohisto-chemistry and outcome in feline injection site sarcomas with known P53status[J]. J Comparative Pathol,2016,154(1):109-109.
[3]蒋小雯,王文娴,张沂平.埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析[J].中国肺癌杂志,2016,19(4):200-206.Jiang XW,Wang WX,Zhang YP. Clinical analysis of icteninib in the treatment of advanced non-small cell lung cancer patients with EGFR-sensitive mutations[J]. Chin J Lung Cancer,2016,19(4):200-206.
[4]潘莹,龚五星,梁翠微,等.晚期非小细胞肺癌靶向治疗进展后的临床研究[J].实用医学杂志,2016,32(3):437-439.Pan Y,Gong WX,Liang CW,et al. Clinical study on advanced treatment of advanced non-small cell lung cancer[J]. J Pract Med,2016,32(3):437-439.
[5] Keating GM. Nivolumab:A review in advanced nonsquamous nonsmall cell lung cancer[J]. Drugs,2016,76(9):969-978.
[6]陆守荣,温浩,宋惠珠,等.艾迪注射液联合紫杉醇与奥沙利铂化疗治疗老年中晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(18):1660-1662.Lu SR,Wen H,Song HZ,et al. Clinical study of Aidi injection combined with paclitaxel and oxaliplatin in the treatment of elderly patients with advanced non-small cell lung cancer[J]. Chin J Clin Pharmacol,2016,32(18):1660-1662.
[7] Ranjan AP,Mukerjee A,Gdowski A,et al. Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer[J]. J Biomed Nanotechnol,2016,12(4):679-688.
[8]胡彬彬,陈宝清,卢铀.贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展[J].中国肿瘤临床,2017,44(3):129-135.Hu BB,Chen BQ,Lu Y. Clinical research progress in the efficacy and safety of bevacizumab in the treatment of advanced non-small cell lung cancer[J]. Chin J Clin Oncol,2017,44(3):129-135.
[9]杨晟,王燕,胡兴胜,等.西妥昔单抗联合化疗治疗晚期非小细胞肺癌的临床疗效分析[J].中国肺癌杂志,2016,19(5):263-268.Yang S,Wang Y,Hu XS,et al. Clinical efficacy analysis of cetuximab combined with chemotherapy for advanced non-small cell lung cancer[J]. Chin J Lung Cancer,2016,19(5):263-268.
[10]孔倩,王心悦,蒋日成,等.不同二线方案治疗178例晚期非小细胞肺癌的预后及影响因素[J].中华肿瘤杂志,2016,38(4):294-299.Kong Q,Wang XY,Jiang RC,et al. Prognosis and influencing factors of 178 cases of advanced non-small cell lung cancer treated with different second-line regimens[J]. Chin J Cancer,2016,38(4):294-299.
[11] Ra HJ,Brakesilla G,Eruslanov E,et al. Abstract PR07:Characterization of human effectors in the tumor microenvironment of NSCLC patients and lung tumor xenograft models[J]. Cancer Res,2016,76(3 Supplement):PR07-PR07.
[12]唐宛豫,张国伟,王慧娟,等. PD-1/PD-L1抑制剂在晚期非小细胞肺癌中的临床进展与治疗策略[J].中国免疫学杂志,2016,32(10):1558-1561.Tang WY,Zhang GW,Wang HJ,et al. Clinical progress and therapeutic strategies of PD-1/PD-L1 inhibitors in advanced nonsmall cell lung cancer[J]. Chin J Immunol,2016,32(10):1558-1561.
[13]麦泽锋.乌苯美司联合紫杉醇与顺铂方案治疗晚期非小细胞肺癌的临床疗效及对免疫功能的影响[J].中国老年学杂志,2016,36(15):3731-3733.Mai ZF. Effects of Ubenomes combined with paclitaxel and cisplatin on the treatment of advanced non-small cell lung cancer and its impact on immune function[J]. Chin J Gerontol,2016,36(15):3731-3733.
[14] Zhang D,Wu J,Liu S,et al. Network meta-analysis of Chinese herbal injections combined with the chemotherapy for the treatment of pancreatic cancer[J]. Medicine,2017,96(21):e7005.
[15]徐咏梅,杨国旺,胡凤山,等.中药辅助动脉灌注化疗治疗晚期非小细胞肺癌53例临床疗效观察[J].中医杂志,2017,58(2):137-141.Xu YM,Yang GW,Hu FS,et al. Clinical observation of traditional Chinese medicine assisted arterial infusion chemotherapy in the treatment of advanced non-small cell lung cancer in 53 cases[J].J Traditional Chin Med,2017,58(2):137-141.
[16]刘冬英,吴海鹰,曾涌波,等. INP和AP方案三线治疗晚期非小细胞肺癌的近期疗效观察[J].中华肿瘤防治杂志,2016,23(21):1441-1445.Liu DY,Wu HY,Zeng YB,et al.. The short-term efficacy of INP and AP regimen three-line therapy for advanced non-small cell lung cancer[J]. Chin J Cancer Prevention Treatment,2016,23(21):1441-1445.
[17] Zang A,Stephansson O,Stenberg L,et al. Hydraulic fracture monitoring in hard rock at 410 m depth with an advanced fluidinjection protocol and extensive sensor array[J]. Geophysical J International,2017,208(2):ggw430.
[18]黄世杰.新一代ALK/ROS1酪氨酸激酶抑制剂劳拉替尼治疗晚期非小细胞肺癌获预期值[J].国际药学研究杂志,2016,43(4):756-756.Huang SJ. A new generation of ALK/ROS1 tyrosine kinase inhibitor lauratinib in the treatment of advanced non-small cell lung cancer with expected value[J]. Int J Pharmaceut Sci,2016,43(4):756-756.
[19]邢镨元,郝学志,王燕,等.白蛋白结合型紫杉醇治疗老年晚期非小细胞肺癌的临床评估[J].中华肿瘤杂志,2016,38(8):615-619.Xing YY,Hao XZ,Wang Y,et al. Clinical evaluation of albuminbound paclitaxel in the treatment of elderly patients with advanced non-small cell lung cancer[J]. Chin J Cancer,2016,38(8):615-619.
[20] Wang C,Guo W,Zhou M,et al. The predictive and prognostic value of early metabolic response assessed by positron emission tomography in advanced gastric cancer treated with chemotherapy[J]. Clin Cancer Res,2016,22(7):1603-1610.
[21]张瑜,彭枫.克唑替尼治疗晚期非小细胞肺癌研究进展[J].肿瘤防治研究,2017,44(11):774-778.Zhang Y,Peng F. Research progress of crizotinib in advanced non-small cell lung cancer[J]. Cancer Res Prevention Treatment,2017,44(11):774-778.
[22] Heier JS,Kherani S,Desai S,et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration:a phase 1,open-label trial[J]. Lancet,2017,390(10089):50.
[23]李小江,姜珊,郭姗琦,等.阿帕替尼联合消岩汤治疗晚期非鳞非小细胞肺癌临床疗效观察[J].中国肿瘤临床,2017,44(14):701-705.Li XJ,Jiang S,Guo YQ,et al. Clinical efficacy of apatinib combined with Xiaoyan Decoction in the treatment of advanced non-squamous non-small cell lung cancer[J]. Chin J Clin Oncol,2017,44(14):701-705.
[24]周强,孙浩珍.多西他赛注射剂治疗晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(21):1964-1966.Zhou Q,Sun HZ. Clinical study of docetaxel injection in the treatment of advanced non-small cell lung cancer[J]. Chin J Clin Pharmacol,2016,32(21):1964-1966.
[25] Miller CM,Donner AJ,Blank EE,et al. Stabilin-1 and Stabilin-2are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides(ASOs)in the liver[J]. Nucl Acids Res,2016,44(6):2782.
[26]黄万钟,周锋,潘达超,等.埃克替尼与标准二线化疗治疗晚期非小细胞肺癌的效果及安全性[J].广东医学,2016,37(s1):184-186.Huang WZ,Zhou F,Pan DC,et al. Efficacy and safety of icotinib and standard second-line chemotherapy in the treatment of advanced non-small cell lung cancer[J]. Guangdong Med J,2016,37(s1):184-186.
[27]王晓莉,王财,殷麟.吉非替尼联合平消胶囊治疗中晚期非小细胞肺癌临床疗效观察[J].中药材,2017,40(3):724-726.Wang XL,Wang C,Yin L. Clinical efficacy of gefitinib combined with Pingxiao capsule in the treatment of advanced non-small cell lung cancer[J]. J Chin Med Materials,2017,40(3):724-726.
[28] Geng R,Roy A,Zhao W,et al. Engineering of spin injection and spin transport in organic spin valves usingπ-conjugated polymer brushes[J]. Adv Functional Materials,2016,26(22):3999-4006.
[29]石荟,白冲.晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识解读(2016年版)[J].中国实用内科杂志,2017,37(2):127-131.Shi H,Bai C. Explanation of expert consensus on anti-angiogenic drugs for advanced non-small cell lung cancer in China's respiratory field(2016 edition)[J]. Chin J Pract Int Med,2017,37(2):127-131.
[30]魏玉娜,王颖,曾明.平消胶囊(片)联合以铂类为基础的化疗方案治疗晚期非小细胞肺癌的Meta分析[J].中成药,2017,39(10):2216-2221.Wei YN,Wang Y,Zeng M. Meta-analysis of the treatment of advanced non-small-cell lung cancer by Pingxiao Capsule(Pan)combined with platinum-based chemotherapy regimen[J]. Chin Tradit Patent Med,2017,39(10):2216-2221.
[2] Küchler A,Buser F,Bley CR,et al. MDM2 immunohisto-chemistry and outcome in feline injection site sarcomas with known P53status[J]. J Comparative Pathol,2016,154(1):109-109.
[3]蒋小雯,王文娴,张沂平.埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析[J].中国肺癌杂志,2016,19(4):200-206.Jiang XW,Wang WX,Zhang YP. Clinical analysis of icteninib in the treatment of advanced non-small cell lung cancer patients with EGFR-sensitive mutations[J]. Chin J Lung Cancer,2016,19(4):200-206.
[4]潘莹,龚五星,梁翠微,等.晚期非小细胞肺癌靶向治疗进展后的临床研究[J].实用医学杂志,2016,32(3):437-439.Pan Y,Gong WX,Liang CW,et al. Clinical study on advanced treatment of advanced non-small cell lung cancer[J]. J Pract Med,2016,32(3):437-439.
[5] Keating GM. Nivolumab:A review in advanced nonsquamous nonsmall cell lung cancer[J]. Drugs,2016,76(9):969-978.
[6]陆守荣,温浩,宋惠珠,等.艾迪注射液联合紫杉醇与奥沙利铂化疗治疗老年中晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(18):1660-1662.Lu SR,Wen H,Song HZ,et al. Clinical study of Aidi injection combined with paclitaxel and oxaliplatin in the treatment of elderly patients with advanced non-small cell lung cancer[J]. Chin J Clin Pharmacol,2016,32(18):1660-1662.
[7] Ranjan AP,Mukerjee A,Gdowski A,et al. Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer[J]. J Biomed Nanotechnol,2016,12(4):679-688.
[8]胡彬彬,陈宝清,卢铀.贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展[J].中国肿瘤临床,2017,44(3):129-135.Hu BB,Chen BQ,Lu Y. Clinical research progress in the efficacy and safety of bevacizumab in the treatment of advanced non-small cell lung cancer[J]. Chin J Clin Oncol,2017,44(3):129-135.
[9]杨晟,王燕,胡兴胜,等.西妥昔单抗联合化疗治疗晚期非小细胞肺癌的临床疗效分析[J].中国肺癌杂志,2016,19(5):263-268.Yang S,Wang Y,Hu XS,et al. Clinical efficacy analysis of cetuximab combined with chemotherapy for advanced non-small cell lung cancer[J]. Chin J Lung Cancer,2016,19(5):263-268.
[10]孔倩,王心悦,蒋日成,等.不同二线方案治疗178例晚期非小细胞肺癌的预后及影响因素[J].中华肿瘤杂志,2016,38(4):294-299.Kong Q,Wang XY,Jiang RC,et al. Prognosis and influencing factors of 178 cases of advanced non-small cell lung cancer treated with different second-line regimens[J]. Chin J Cancer,2016,38(4):294-299.
[11] Ra HJ,Brakesilla G,Eruslanov E,et al. Abstract PR07:Characterization of human effectors in the tumor microenvironment of NSCLC patients and lung tumor xenograft models[J]. Cancer Res,2016,76(3 Supplement):PR07-PR07.
[12]唐宛豫,张国伟,王慧娟,等. PD-1/PD-L1抑制剂在晚期非小细胞肺癌中的临床进展与治疗策略[J].中国免疫学杂志,2016,32(10):1558-1561.Tang WY,Zhang GW,Wang HJ,et al. Clinical progress and therapeutic strategies of PD-1/PD-L1 inhibitors in advanced nonsmall cell lung cancer[J]. Chin J Immunol,2016,32(10):1558-1561.
[13]麦泽锋.乌苯美司联合紫杉醇与顺铂方案治疗晚期非小细胞肺癌的临床疗效及对免疫功能的影响[J].中国老年学杂志,2016,36(15):3731-3733.Mai ZF. Effects of Ubenomes combined with paclitaxel and cisplatin on the treatment of advanced non-small cell lung cancer and its impact on immune function[J]. Chin J Gerontol,2016,36(15):3731-3733.
[14] Zhang D,Wu J,Liu S,et al. Network meta-analysis of Chinese herbal injections combined with the chemotherapy for the treatment of pancreatic cancer[J]. Medicine,2017,96(21):e7005.
[15]徐咏梅,杨国旺,胡凤山,等.中药辅助动脉灌注化疗治疗晚期非小细胞肺癌53例临床疗效观察[J].中医杂志,2017,58(2):137-141.Xu YM,Yang GW,Hu FS,et al. Clinical observation of traditional Chinese medicine assisted arterial infusion chemotherapy in the treatment of advanced non-small cell lung cancer in 53 cases[J].J Traditional Chin Med,2017,58(2):137-141.
[16]刘冬英,吴海鹰,曾涌波,等. INP和AP方案三线治疗晚期非小细胞肺癌的近期疗效观察[J].中华肿瘤防治杂志,2016,23(21):1441-1445.Liu DY,Wu HY,Zeng YB,et al.. The short-term efficacy of INP and AP regimen three-line therapy for advanced non-small cell lung cancer[J]. Chin J Cancer Prevention Treatment,2016,23(21):1441-1445.
[17] Zang A,Stephansson O,Stenberg L,et al. Hydraulic fracture monitoring in hard rock at 410 m depth with an advanced fluidinjection protocol and extensive sensor array[J]. Geophysical J International,2017,208(2):ggw430.
[18]黄世杰.新一代ALK/ROS1酪氨酸激酶抑制剂劳拉替尼治疗晚期非小细胞肺癌获预期值[J].国际药学研究杂志,2016,43(4):756-756.Huang SJ. A new generation of ALK/ROS1 tyrosine kinase inhibitor lauratinib in the treatment of advanced non-small cell lung cancer with expected value[J]. Int J Pharmaceut Sci,2016,43(4):756-756.
[19]邢镨元,郝学志,王燕,等.白蛋白结合型紫杉醇治疗老年晚期非小细胞肺癌的临床评估[J].中华肿瘤杂志,2016,38(8):615-619.Xing YY,Hao XZ,Wang Y,et al. Clinical evaluation of albuminbound paclitaxel in the treatment of elderly patients with advanced non-small cell lung cancer[J]. Chin J Cancer,2016,38(8):615-619.
[20] Wang C,Guo W,Zhou M,et al. The predictive and prognostic value of early metabolic response assessed by positron emission tomography in advanced gastric cancer treated with chemotherapy[J]. Clin Cancer Res,2016,22(7):1603-1610.
[21]张瑜,彭枫.克唑替尼治疗晚期非小细胞肺癌研究进展[J].肿瘤防治研究,2017,44(11):774-778.Zhang Y,Peng F. Research progress of crizotinib in advanced non-small cell lung cancer[J]. Cancer Res Prevention Treatment,2017,44(11):774-778.
[22] Heier JS,Kherani S,Desai S,et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration:a phase 1,open-label trial[J]. Lancet,2017,390(10089):50.
[23]李小江,姜珊,郭姗琦,等.阿帕替尼联合消岩汤治疗晚期非鳞非小细胞肺癌临床疗效观察[J].中国肿瘤临床,2017,44(14):701-705.Li XJ,Jiang S,Guo YQ,et al. Clinical efficacy of apatinib combined with Xiaoyan Decoction in the treatment of advanced non-squamous non-small cell lung cancer[J]. Chin J Clin Oncol,2017,44(14):701-705.
[24]周强,孙浩珍.多西他赛注射剂治疗晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(21):1964-1966.Zhou Q,Sun HZ. Clinical study of docetaxel injection in the treatment of advanced non-small cell lung cancer[J]. Chin J Clin Pharmacol,2016,32(21):1964-1966.
[25] Miller CM,Donner AJ,Blank EE,et al. Stabilin-1 and Stabilin-2are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides(ASOs)in the liver[J]. Nucl Acids Res,2016,44(6):2782.
[26]黄万钟,周锋,潘达超,等.埃克替尼与标准二线化疗治疗晚期非小细胞肺癌的效果及安全性[J].广东医学,2016,37(s1):184-186.Huang WZ,Zhou F,Pan DC,et al. Efficacy and safety of icotinib and standard second-line chemotherapy in the treatment of advanced non-small cell lung cancer[J]. Guangdong Med J,2016,37(s1):184-186.
[27]王晓莉,王财,殷麟.吉非替尼联合平消胶囊治疗中晚期非小细胞肺癌临床疗效观察[J].中药材,2017,40(3):724-726.Wang XL,Wang C,Yin L. Clinical efficacy of gefitinib combined with Pingxiao capsule in the treatment of advanced non-small cell lung cancer[J]. J Chin Med Materials,2017,40(3):724-726.
[28] Geng R,Roy A,Zhao W,et al. Engineering of spin injection and spin transport in organic spin valves usingπ-conjugated polymer brushes[J]. Adv Functional Materials,2016,26(22):3999-4006.
[29]石荟,白冲.晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识解读(2016年版)[J].中国实用内科杂志,2017,37(2):127-131.Shi H,Bai C. Explanation of expert consensus on anti-angiogenic drugs for advanced non-small cell lung cancer in China's respiratory field(2016 edition)[J]. Chin J Pract Int Med,2017,37(2):127-131.
[30]魏玉娜,王颖,曾明.平消胶囊(片)联合以铂类为基础的化疗方案治疗晚期非小细胞肺癌的Meta分析[J].中成药,2017,39(10):2216-2221.Wei YN,Wang Y,Zeng M. Meta-analysis of the treatment of advanced non-small-cell lung cancer by Pingxiao Capsule(Pan)combined with platinum-based chemotherapy regimen[J]. Chin Tradit Patent Med,2017,39(10):2216-2221.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |